|
Basic Characteristics of Mutations
|
|
Mutation Site
|
D614G |
|
Mutation Site Sentence
|
SARS-CoV-2 BA.2: accession number: EPI_ISL_9652748:T19I, L24S, del25/27, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K; |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
S |
|
Standardized Encoding Gene
|
S
|
|
Genotype/Subtype
|
BA.2;BA.4/BA.5;BA.2.12.1;BA.2.75 |
|
Viral Reference
|
NC_045512
|
|
Functional Impact and Mechanisms
|
|
Disease
|
COVID-19
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
36925722
|
|
Title
|
Additional mutations based on Omicron BA.2.75 mediate its further evasion from broadly neutralizing antibodies
|
|
Author
|
Guo H,Jiang J,Shen S,Ge X,Fan Q,Zhou B,Cheng L,Ju B,Zhang Z
|
|
Journal
|
iScience
|
|
Journal Info
|
2023 Apr 21;26(4):106283
|
|
Abstract
|
SARS-CoV-2 Omicron BA.2.75 subvariant has evolved to a series of progeny variants carrying several additional mutations in the receptor-binding domain (RBD). Here, we investigated whether and how these single mutations based on BA.2.75 affect the neutralization of currently available anti-RBD monoclonal antibodies (mAbs) with well-defined structural information. Approximately 34% of mAbs maintained effective neutralizing activities against BA.2.75, consistent with those against BA.2, BA.4/5, and BA.2.12.1. Single additional R346T, K356T, L452R, or F486S mutations further facilitated BA.2.75-related progeny variants to escape from broadly neutralizing antibodies (bnAbs) at different degree. Only LY-CoV1404 (bebtelovimab) displayed a first-class neutralization potency and breadth against all tested Omicron subvariants. Overall, these data make a clear connection between virus escape and antibody recognizing antigenic epitopes, which facilitate to develop next-generation universal bnAbs against emerging SARS-CoV-2 variants.
|
|
Sequence Data
|
EPI_ISL_9652748;EPI_ISL_11542550;EPI_ISL_9767878;EPI_ISL_13502576
|
|
|